α-干扰素联合胸腺肽治疗慢性乙型肝炎过程中IL-12水平的动态变化  

The level of IL-12 of chronic hepatitis B patients during the treatment with interferon αcombination with thymus peptide

作　　者：李俐[1] 马颖哲[1] 孙国光[1] 张桂荣[1] 

机构地区：[1]吉林大学基础医学院生物化学与分子生物学中心实验室,吉林长春130021

出　　处：《中国老年学杂志》2010年第11期1491-1492,共2页Chinese Journal of Gerontology

基　　金：吉林省科技发展计划项目(20070425;200705368)

摘　　要：目的动态观察α-干扰素联合胸腺肽治疗慢性乙型肝炎(CHB)过程中患者外周血IL-12水平,观察CHB患者对干扰素联合胸腺肽治疗的反应及免疫状态。方法 100例患者随机分为α-干扰素联合胸腺肽组和α-干扰素组,采用ELISA方法及PCR方法检测各组IL-12和HBV-DNA含量,同时观察各组ALT水平的变化。结果治疗结束时联合组与干扰素组比较,IL-12水平明显增加(P<0.05),联合组血清HBVDNA阴转率及ALT复常率指标也均优于干扰素组,且治疗结束后仍维持较长时间。结论 IL-12参与CHB的发病机制,并可作为评估干扰素联合胸腺肽抗病毒治疗的重要免疫指标。胸腺肽联合干扰素治疗CHB比单独使用干扰素疗效更好、更持久。Objective To observe the level of IL-12 of chronic hepatitis B（CHB） patients during the treatment with interferon αcombination with thymus peptide to forecast the therapeutic effect and the immune state.Methods 100 CHB patients were stochastically divided into interferon union thymus peptide and interferon groups.The level of IL-12 was tested by ELISA and the content of HBV-DNA was tested by PCR.Results At the end of treatment,the level of IL-12 of interferon union thymus peptide group was increased than that of interferon group （P 〈0.05）,the negative rate of HBV DNA and ALT were higher in interferon union thymus peptide group than that of interferon group （P〈 0.05） and after treatment it still maintained for a long time.Conclusions IL-12 participates in the pathogenesis of CHB,and may takes an important indicator of assessing the anti-virus therapeutic effect of interferon combination with thymus peptide.The effect of thymus peptide combination with interferon for CHB is better and more lasting than the treatment of interferon.

关 键 词：慢性乙型肝炎(CHB) 干扰素 胸腺肽 

分 类 号：R512.6[医药卫生—内科学]